Implementation of 2023 Canadian Thoracic Society Guidelines for Single-Inhaler Triple Therapy Could Reduce Exacerbation and Mortality Rates in COPD: PROMETHEUS Canada

Mohit Bhutani; Alan Kaplan; Sheena Kayaniyil; Kyla C. Jamieson; Ross Ormsby; John Bell; Prachi Bhatt; Jennifer Carioto; Bruce Pyenson

doi:10.15326/jcopdf.2025.0687

January 1, 2026Chronic Obstructive Pulmonary Diseases Journal of the COPD FoundationOpen Access

Implementation of 2023 Canadian Thoracic Society Guidelines for Single-Inhaler Triple Therapy Could Reduce Exacerbation and Mortality Rates in COPD: PROMETHEUS Canada

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research aims to evaluate the effects of implementing the 2023 Canadian Thoracic Society guidelines for single-inhaler triple therapy (SITT) in COPD patients.
Analysis of 2023 Canadian Thoracic Society guidelines for COPD treatment.
Assessment of patient outcomes related to exacerbation frequency.
Estimation of potential mortality reduction and associated healthcare costs.
Adopting SITT could significantly lower the frequency of exacerbations in COPD.
Lower mortality rates were projected with appropriate use of guidelines.
Overall, healthcare costs related to COPD management could decrease substantially.

Implication

Analysis shows implementing new guidelines reduces exacerbation and mortality in COPD, suggesting improved patient outcomes.

Abstract

Appropriate use of SITT informed by the 2023 CTS COPD guidelines could lower mortality, exacerbation frequency and their corresponding costs in patients with COPD.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Bhutani et al. (2026) studied this question.

synapsesocial.com/papers/69cf58285a333a8214609733 https://doi.org/10.15326/jcopdf.2025.0687

View Full Paper

Ask AI

Bookmark

Share

Implementation of 2023 Canadian Thoracic Society Guidelines for Single-Inhaler Triple Therapy Could Reduce Exacerbation and Mortality Rates in COPD: PROMETHEUS Canada

Key Points

Implication

Abstract

Discussion

Cite This Study

Implementation of 2023 Canadian Thoracic Society Guidelines for Single-Inhaler Triple Therapy Could Reduce Exacerbation and Mortality Rates in COPD: PROMETHEUS Canada

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation

Keep reading

More related papers

More from Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation